Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency

NCT06827353 · clinicaltrials.gov ↗

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Carcinoma

Interventions

DRUG: maintenance therapy with bevacizumab
DRUG: maintenance therapy with niraparib

Sponsor

Centre Hospitalier Universitaire de Nīmes